Biomarker for diagnosing pre-chemotherapy resistance in solid cancer patients and method for providing information for diagnosing pre-chemotherapy resistance, using same
AssigneesThe Asan Foundation, University of Ulsan Foundation for Industry Cooperation
InventorsDong-Myung SHIN, Yong-Mee CHO, Yonghwan KIM
Life of this patent
Estimating the term…
Abstract
Biomarkers useful for detecting resistance to platinum-based chemotherapeutic agents (e.g., cisplatin) administered as pre-chemotherapy (NAC) for solid tumors (e.g., muscle-invasive bladder cancer (MIBC)). The biomarkers include glutathione-related genes, the expression levels of which can be used to determine the NAC resistance. The biomarkers are used in a method of determining chemotherapy resistance and in a method of treating a cancer in a subject.
Claims22
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composition for diagnosing chemotherapy resistance in a solid cancer patient, comprising an agent for measuring an expression level of a glutathione-related gene.
A method for determining chemotherapy resistance in a subject having a solid cancer, the method comprising:
- measuring an expression level of a glutathione-related gene from a sample isolated from the subject;
- comparing the expression level of the glutathione-related gene with that of a normal control group sample;
- and
- determining that the subject has a chemotherapy resistance when the expression level of the glutathione-related gene measured from the sample isolated from the subject is different from that of the normal control group sample.
A method for treating a solid cancer in a subject in need thereof, the method comprising:
- measuring an expression level of a glutathione-related gene from a sample isolated from the subject;
- comparing the expression level of the glutathione-related gene with that of a normal control group sample;
- determining that the subject has a chemotherapy resistance when the expression level of the glutathione-related gene measured from the sample isolated from the subject is different from that of the normal control group sample;
- and
- administering to the subject an anticancer agent.
Dependencies are inferred from the claim text.